AS Latvijas Juras medicinas centrs Valuation
Is LJM1R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of LJM1R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: LJM1R (€8) is trading above our estimate of fair value (€1.75)
Significantly Below Fair Value: LJM1R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LJM1R?
Other financial metrics that can be useful for relative valuation.
What is LJM1R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | €7.20m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.7x |
Enterprise Value/EBITDA | 12.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does LJM1R's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.1x | ||
530897 N G Industries | 3.3x | n/a | ₹545.5m |
SANGANI Sangani Hospitals | 3.5x | n/a | ₹613.1m |
8143 Good Fellow Healthcare Holdings | 1.2x | n/a | HK$64.2m |
7362 Terminalcare Support Institute | 0.4x | n/a | JP¥1.6b |
LJM1R AS Latvijas Juras medicinas centrs | 0.7x | n/a | €7.2m |
Price-To-Sales vs Peers: LJM1R is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (2.1x).
Price to Earnings Ratio vs Industry
How does LJM1R's PE Ratio compare vs other companies in the European Healthcare Industry?
Price-To-Sales vs Industry: LJM1R is expensive based on its Price-To-Sales Ratio (0.7x) compared to the European Healthcare industry average (0.7x).
Price to Sales Ratio vs Fair Ratio
What is LJM1R's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.7x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate LJM1R's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.